Phaarmasia Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 306122,
    "name": "Phaarmasia",
    "stock_name": "Phaarmasia",
    "full_name": "Phaarmasia Ltd",
    "name_url": "stocks-analysis/phaarmasia",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "79.50",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "79.50",
    "mcapval": "54.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 523620,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE486I01016",
    "curr_date": "Jun 03, 03:30 PM",
    "curr_time": "23:56 PM",
    "last_traded_at": "Jun 03, 03:30 PM IST",
    "bse_nse_vol": "3 ",
    "exc_status": "Active",
    "traded_date": "Jun 03, 2026",
    "traded_date_str": "2026 06 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/phaarmasia-306122-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Phaarmasia Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Mixed Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/phaarmasia-ltd-valuation-shifts-signal-renewed-price-attractiveness-amid-mixed-returns-4029113",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/PhaarmasiaLtd_valuationdot_4029113.png",
        "date": "2026-06-02 08:01:11",
        "description": "Phaarmasia Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive grade, reflecting evolving market perceptions amid a challenging pharmaceutical sector. Despite a recent downgrade in its Mojo Grade from Hold to Sell, the company’s valuation metrics suggest a more compelling price entry point relative to its historical averages and peer group, warranting a closer examination for investors seeking micro-cap opportunities in Pharmaceuticals & Biotechnology."
      },
      {
        "title": "Phaarmasia Ltd Q4 FY26: Quarterly Loss Amid Revenue Volatility Raises Sustainability Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/phaarmasia-ltd-q4-fy26-quarterly-loss-amid-revenue-volatility-raises-sustainability-concerns-4024490",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/Phaarmasia_quaterlyResult_4024490.png",
        "date": "2026-05-30 23:47:48",
        "description": "Phaarmasia Limited (NSE: PHAARMASIA, BSE: 523620), a micro-cap pharmaceutical manufacturer specialising in hormonal contraceptive tablets, reported a troubling quarter-on-quarter deterioration in Q4 FY26, posting a net loss of ₹0.70 crores against a profit of ₹16.27 crores in the previous quarter. The Hyderabad-based company, with a modest market capitalisation of ₹53.00 crores, saw its net sales plummet 51.84% sequentially to ₹7.73 crores, raising serious questions about revenue sustainability and operational stability."
      },
      {
        "title": "Phaarmasia Ltd is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/phaarmasia-ltd-is-rated-hold-by-marketsmojo-4019930",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/PhaarmasiaLtd_mojoScore_4019930.png",
        "date": "2026-05-29 10:10:42",
        "description": "Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 Feb 2026. While the rating was revised earlier this year, the analysis below reflects the stock’s current fundamentals, returns, and financial metrics as of 29 May 2026, providing investors with an up-to-date view of the company’s position in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Phaarmasia Ltd is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/phaarmasia-ltd-is-rated-hold-by-marketsmojo-3996709",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/PhaarmasiaLtd_mojoScore_3996709.png",
        "date": "2026-05-18 10:10:30",
        "description": "Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 Feb 2026. However, the analysis and financial metrics discussed below reflect the company’s current position as of 18 May 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Phaarmasia Ltd Valuation Shift Signals Renewed Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/phaarmasia-ltd-valuation-shift-signals-renewed-price-attractiveness-3988400",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/PhaarmasiaLtd_valuationdot_3988400.png",
        "date": "2026-05-13 08:00:22",
        "description": "Phaarmasia Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive grade. This change reflects evolving market perceptions and invites a closer examination of its price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to historical trends and peer benchmarks."
      },
      {
        "title": "Phaarmasia Ltd is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/phaarmasia-ltd-is-rated-hold-by-marketsmojo-3975768",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/PhaarmasiaLtd_mojoScore_3975768.png",
        "date": "2026-05-05 10:10:34",
        "description": "Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 Feb 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 05 May 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Phaarmasia Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/phaarmasia-ltd-valuation-shifts-signal-renewed-price-attractiveness-amid-sector-dynamics-3963486",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/PhaarmasiaLtd_valuationdot_3963486.png",
        "date": "2026-04-27 08:00:16",
        "description": "Phaarmasia Ltd has witnessed a significant improvement in its valuation parameters, shifting from an 'attractive' to a 'very attractive' grade, reflecting a notable change in investor sentiment. Despite a recent 3.5% dip in its share price, the micro-cap pharmaceutical company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now position it favourably against both historical benchmarks and peer averages, signalling potential value opportunities for discerning investors."
      },
      {
        "title": "Phaarmasia Ltd is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/phaarmasia-ltd-is-rated-hold-by-marketsmojo-3960611",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/PhaarmasiaLtd_mojoScore_3960611.png",
        "date": "2026-04-24 10:10:31",
        "description": "Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 Feb 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 24 April 2026, providing investors with the latest insights into its performance and outlook."
      },
      {
        "title": "Phaarmasia Ltd Valuation Shifts Signal Renewed Investor Interest Amid Sector Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/phaarmasia-ltd-valuation-shifts-signal-renewed-investor-interest-amid-sector-challenges-3946412",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/PhaarmasiaLtd_valuationdot_3946412.png",
        "date": "2026-04-15 08:00:42",
        "description": "Phaarmasia Ltd has witnessed a notable improvement in its valuation parameters, shifting from a very attractive to an attractive rating, signalling a renewed price appeal for investors. This micro-cap pharmaceutical player’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios, alongside other key metrics, suggest a more favourable investment proposition compared to its historical averages and peer group benchmarks."
      }
    ],
    "total": 728,
    "sid": "306122",
    "stock_news_url": "https://www.marketsmojo.com/news/phaarmasia-306122"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "01-Jun-2026",
      "details": "Newspaper Advertisement of the Audited Financial Results for the Quarter and year ended 31st March 2026",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On Friday 29Th May 2026",
      "datetime": "29-May-2026",
      "details": "Pursuant to Regulation 30 read with Regulation 33 of SEBI (Listing Obligation and Disclosure Requirement) Regulations 2015 we would like to inform you that the meeting of Board of Directors of Phaarmasia Limited was held on Friday 29th day of May 2026 at 04:30 PM and concluded at 05:30 PM. Inter-alia the Board discussed and passed the following resolutions: 1. Approved the audited financial results of the Company for the quarter and year ended 31st March 2026. 2. Approved the Auditors report on the financial statements of the Company for the Financial year ended 31st March 2026. 3. Approved the appointment of Internal Auditors of the Company for the financial year 2026-27. 4. Approved the appointment of Secretarial Auditors of the Company for the financial year 2025-26.",
      "source": "BSE"
    },
    {
      "caption": "Integrated Filing Of Financials For The Quarter And FY Ended 31St March 2026",
      "datetime": "29-May-2026",
      "details": "Submission of Integrated Filing of Financials for the Quarter and FY ended 31st March 2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Phaarmasia Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Mixed Returns

2026-06-02 08:01:11

Phaarmasia Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive grade, reflecting evolving market perceptions amid a challenging pharmaceutical sector. Despite a recent downgrade in its Mojo Grade from Hold to Sell, the company’s valuation metrics suggest a more compelling price entry point relative to its historical averages and peer group, warranting a closer examination for investors seeking micro-cap opportunities in Pharmaceuticals & Biotechnology.

Read full news article

Phaarmasia Ltd Q4 FY26: Quarterly Loss Amid Revenue Volatility Raises Sustainability Concerns

2026-05-30 23:47:48

Phaarmasia Limited (NSE: PHAARMASIA, BSE: 523620), a micro-cap pharmaceutical manufacturer specialising in hormonal contraceptive tablets, reported a troubling quarter-on-quarter deterioration in Q4 FY26, posting a net loss of ₹0.70 crores against a profit of ₹16.27 crores in the previous quarter. The Hyderabad-based company, with a modest market capitalisation of ₹53.00 crores, saw its net sales plummet 51.84% sequentially to ₹7.73 crores, raising serious questions about revenue sustainability and operational stability.

Read full news article

Phaarmasia Ltd is Rated Hold by MarketsMOJO

2026-05-29 10:10:42

Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 Feb 2026. While the rating was revised earlier this year, the analysis below reflects the stock’s current fundamentals, returns, and financial metrics as of 29 May 2026, providing investors with an up-to-date view of the company’s position in the Pharmaceuticals & Biotechnology sector.

Read full news article

Phaarmasia Ltd is Rated Hold by MarketsMOJO

2026-05-18 10:10:30

Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 Feb 2026. However, the analysis and financial metrics discussed below reflect the company’s current position as of 18 May 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Phaarmasia Ltd Valuation Shift Signals Renewed Price Attractiveness

2026-05-13 08:00:22

Phaarmasia Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive grade. This change reflects evolving market perceptions and invites a closer examination of its price-to-earnings (P/E) and price-to-book value (P/BV) ratios relative to historical trends and peer benchmarks.

Read full news article

Phaarmasia Ltd is Rated Hold by MarketsMOJO

2026-05-05 10:10:34

Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 Feb 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 05 May 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Phaarmasia Ltd Valuation Shifts Signal Renewed Price Attractiveness Amid Sector Dynamics

2026-04-27 08:00:16

Phaarmasia Ltd has witnessed a significant improvement in its valuation parameters, shifting from an 'attractive' to a 'very attractive' grade, reflecting a notable change in investor sentiment. Despite a recent 3.5% dip in its share price, the micro-cap pharmaceutical company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios now position it favourably against both historical benchmarks and peer averages, signalling potential value opportunities for discerning investors.

Read full news article

Phaarmasia Ltd is Rated Hold by MarketsMOJO

2026-04-24 10:10:31

Phaarmasia Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 Feb 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 24 April 2026, providing investors with the latest insights into its performance and outlook.

Read full news article

Phaarmasia Ltd Valuation Shifts Signal Renewed Investor Interest Amid Sector Challenges

2026-04-15 08:00:42

Phaarmasia Ltd has witnessed a notable improvement in its valuation parameters, shifting from a very attractive to an attractive rating, signalling a renewed price appeal for investors. This micro-cap pharmaceutical player’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios, alongside other key metrics, suggest a more favourable investment proposition compared to its historical averages and peer group benchmarks.

Read full news article

View All News